Deals
Growth Concerns Loom For Daiichi Sankyo on Drug Warning: Health
This article is for subscribers only.
Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the Japanese drugmaker’s plans to fill the gap have hit a roadblock and investors worry that growth may flounder.
The Tokyo-based company’s best-selling medicine is set to lose patent protection in 2016, and a new blood thinner had been seen as one of its best chances to offset the hit. Instead, a U.S. regulatory warning placed on the new drug’s packaging may limit its market potential.